Swift Molecular Diagnostics
SwiftDx is a molecular diagnostic company dedicated to revolutionizing diagnostics by developing innovative, ultra-sensitive lateral flow tests utilizing proprietary technologies like eAMP. Their mission is to create high-quality, accessible point-of-care diagnostic tests that can detect diseases currently undetectable with existing lateral flow technology, thereby improving global health outcomes.
Industries
Nr. of Employees
small (1-50)
Swift Molecular Diagnostics
Bio-Innovation Centre, 25 Cambridge Science Park, Milton Road, Cambridge, CB4 0FW
Products
Mycoplasma Detection Kit
A kit combining a modified PCR reaction with lateral flow detection to rapidly detect mycoplasma contamination from 2 µL of cell culture media; provides a simple lateral flow positive/negative result and claims high sensitivity.
High-sensitivity Dengue rapid test (in development)
Planned ultra-sensitive lateral flow test intended to detect dengue through antigen and antibody detection in a rapid, community-deployable format.
Early HIV detection LFA (in development)
Planned high-sensitivity dual antigen/antibody lateral flow assay designed to reduce the detection window and enable earlier identification of HIV infection.
Hepatitis C saliva test (in development)
Planned saliva-based high-sensitivity lateral flow test for HCV designed for self-testing and programmatic delivery, intended to avoid large blood samples.
PSA threshold at-home test (in development)
Planned lateral flow threshold test intended to indicate whether a user's PSA level is above a pre-specified, age-adjusted threshold to support screening and post-treatment monitoring.
Mycoplasma Detection Kit
A kit combining a modified PCR reaction with lateral flow detection to rapidly detect mycoplasma contamination from 2 µL of cell culture media; provides a simple lateral flow positive/negative result and claims high sensitivity.
High-sensitivity Dengue rapid test (in development)
Planned ultra-sensitive lateral flow test intended to detect dengue through antigen and antibody detection in a rapid, community-deployable format.
Early HIV detection LFA (in development)
Planned high-sensitivity dual antigen/antibody lateral flow assay designed to reduce the detection window and enable earlier identification of HIV infection.
Hepatitis C saliva test (in development)
Planned saliva-based high-sensitivity lateral flow test for HCV designed for self-testing and programmatic delivery, intended to avoid large blood samples.
PSA threshold at-home test (in development)
Planned lateral flow threshold test intended to indicate whether a user's PSA level is above a pre-specified, age-adjusted threshold to support screening and post-treatment monitoring.
Services
Commercial sale of a PCR-to-lateral-flow mycoplasma detection kit for routine, rapid mycoplasma screening of cell culture supernatant.
End-to-end development and market introduction of high-sensitivity lateral flow devices using amplification chemistry and DNA-detection methods for point-of-care and self-test applications.
Commercial sale of a PCR-to-lateral-flow mycoplasma detection kit for routine, rapid mycoplasma screening of cell culture supernatant.
End-to-end development and market introduction of high-sensitivity lateral flow devices using amplification chemistry and DNA-detection methods for point-of-care and self-test applications.
Expertise Areas
- Lateral flow assay development
- Signal amplification strategies for diagnostics
- Molecular diagnostics (PCR-to-LFA workflows)
- Assay validation and analytical performance evaluation
Key Technologies
- Enhanced lateral flow signal amplification
- Lateral flow assay (LFA) formats
- Modified PCR for lateral flow readout
- DNA detection on lateral flow
News & Updates
At Cambridge Molecular Diagnostics Limited, a new lateral flow test for Mycoplasma detection has been launched, offering rapid and easy-to-use results.
An article explaining the importance of rapid mycoplasma detection and the new test developed by SwiftDx.
An article discussing the global spread of Dengue Fever and the importance of rapid diagnostics.
Announcement of Professor Denis Kinane joining SwiftDx as Non-Executive Chairman.
At Cambridge Molecular Diagnostics Limited, a new lateral flow test for Mycoplasma detection has been launched, offering rapid and easy-to-use results.
An article explaining the importance of rapid mycoplasma detection and the new test developed by SwiftDx.
An article discussing the global spread of Dengue Fever and the importance of rapid diagnostics.
Announcement of Professor Denis Kinane joining SwiftDx as Non-Executive Chairman.